Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz4. fázis

Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

A legfontosabb adatok

Ki végzi
The University of Texas Medical Branch, Galveston
Hol
Galveston (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Fut, nem toboroz
Fázis
4. fázis
Résztvevők
618 fő vett részt
Kezdés
2023. jan. 18.
Várható befejezés
2028. aug.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • 9-valent HPV vaccine, 2 doses alternate timing
  • 9-valent HPV vaccine, 3 doses standard timing
A regiszteradat frissítve
2026. november 17.

Ki vehet részt

Életkor
27 év – 45 év
Nem
Csak nők
Egészséges önkéntesek
Részt vehetnek
A regiszter összes feltétele (16)A regiszter feltételeinek elrejtése

Ki vehet részt

  • Females 27-45 years old
  • Ability to give informed consent
  • Has not received any prior doses of the HPV vaccine. This will be verified by the person and state registry (Immtrac), as well as the person's electronic medical record
  • Reliable telephone access for the duration of the project
  • Can read and speak in either English or Spanish
  • Identified source of funding for vaccine such as Medicaid, private health insurance, Texas Healthy Women program, etc
  • Reports consistent use of reliable birth control and plans to continue its use through study month 13

Ki nem vehet részt

  • Currently receiving treatment or medication that can suppress immune function including radiation therapy, chemotherapy, cyclosporin, leflunomide (Arava), TNF-α antagonists, monoclonal antibody therapies (including rituximab [Rituxan]), intravenous gamma globulin (IVIG), antilymphocyte sera, other therapy known to interfere with the immune response, or systemic corticosteroids (by mouth or intramuscular injection). Those using or have used steroids that are inhaled, placed in the eye, applied on the skin, or injected into the joint/soft tissue will be considered eligible for the study
  • Febrile at ≥100°F in the 24 hours prior to vaccination. The patients may be rescheduled for a later date
  • Has an immunodeficiency or autoimmune disease such as HIV infection, lymphoma, leukemia, lupus, rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition
  • History of splenectomy
  • Known allergies to any vaccine components, including aluminum, yeast or Benzonase
  • History of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections
  • History of >10 sexual partners in their lifetime at time of enrollment
  • Currently pregnant or plans to become pregnant or donate eggs in the next 13 months. Any subjects with positive pregnancy tests at the initial visit will be disqualified from the study and advised to seek prenatal care
  • Plans to move out of the Galveston/Houston area in the 13 months following study entry

Helyszínek itt: Egyesült Államok

  • University of Texas Medical BranchGalveston, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.

A vizsgálat 2 csoportja

  • Females, 3-dose standardMár használt kezelés, összehasonlításként

    Three doses of the 9-valent HPV vaccine to be administered to the comparison group (27-45 years of age) at 0, 2, and 6 months.

    Kezelés: 9-valent HPV vaccine, 3 doses standard timing

  • Females, 2-dose alternativeA vizsgált kezelés

    Two doses of the 9-valent HPV vaccine to be administered to the experimental group (27-45 years of age) at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.

    Kezelés: 9-valent HPV vaccine, 2 doses alternate timing

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Comparison of the Immune Response After Administration of 2 vs. 3 Doses of the FDA-approved 9-Valent HPV Vaccine Among Women 27-45 Years of Age
Publikációk
A regiszteradat frissítve
2026. november 17.